Cost-utility analysis of tislelizumab in the treatment of locally advanced or metastatic （non-）squamous NSCLC

WANG Chunyan; WU Jing; SHEN Lixia

doi:10.6039/j.issn.1001-0408.2025.11.14

您当前的位置：

首页 >

文章列表页 >

Cost-utility analysis of tislelizumab in the treatment of locally advanced or metastatic （non-）squamous NSCLC

更新时间：2026-02-06

- Cost-utility analysis of tislelizumab in the treatment of locally advanced or metastatic （non-）squamous NSCLC
- ZHONGGUO YAOFANG Vol. 36, Issue 11, Pages: 1370-1374(2025)
- 作者机构：
  
  中国人民解放军海军第九七一医院药剂科，山东青岛　266071
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.11.14
  CLC： R956;R979.1
- Received：06 November 2024，
  
  Revised：2025-05-16，
  
  Accepted：17 May 2025，
  
  Published：15 June 2025
- 稿件说明：
移动端阅览
王春燕,吴婧,沈丽霞.替雷利珠单抗治疗局部晚期或转移性（非）鳞状NSCLC的成本-效用分析 [J].中国药房,2025,36(11):1370-1374.

WANG Chunyan,WU Jing,SHEN Lixia.Cost-utility analysis of tislelizumab in the treatment of locally advanced or metastatic （non-）squamous NSCLC[J].ZHONGGUO YAOFANG,2025,36(11):1370-1374.
王春燕,吴婧,沈丽霞.替雷利珠单抗治疗局部晚期或转移性（非）鳞状NSCLC的成本-效用分析 [J].中国药房,2025,36(11):1370-1374. DOI： 10.6039/j.issn.1001-0408.2025.11.14.

WANG Chunyan,WU Jing,SHEN Lixia.Cost-utility analysis of tislelizumab in the treatment of locally advanced or metastatic （non-）squamous NSCLC[J].ZHONGGUO YAOFANG,2025,36(11):1370-1374. DOI： 10.6039/j.issn.1001-0408.2025.11.14.

摘要

目的

从我国卫生体系角度出发，评价替雷利珠单抗单药治疗既往接受过含铂双药方案化疗后疾病进展或不可耐受的局部晚期或转移性鳞状或非鳞状非小细胞肺癌（NSCLC）患者的经济性。

方法

根据Rationale-303研究数据构建分区生存模型，设定模型周期为21 d，模拟时间为120个月。以质量调整生命年（QALY）为健康产出指标，采用5%的贴现率对成本和健康产出进行贴现，计算增量成本-效果比（ICER），并采用单因素敏感性分析和概率敏感性分析验证基础分析结果的稳健性。

结果

成本-效用分析结果显示，替雷利珠单抗组方案相对于多西他赛组方案的ICER为65 653.52元/QALY，即当意愿支付阈值（WTP）为3倍2023年我国人均国内生产总值（268 200元/QALY）时，替雷利珠单抗组方案比多西他赛组方案更具有经济性。单因素敏感性分析结果显示，对ICER影响程度较大的3个参数分别是替雷利珠单抗成本、多西他赛成本、培美曲塞成本。概率敏感性分析结果显示，当WTP阈值约为65 000元/QALY时，上述两组治疗方案具有经济性的概率均为50%；当WTP阈值≥134 000元/QALY时，替雷利珠单抗组方案具有经济性的概率为100%。

结论

从我国卫生体系角度出发，以3倍2023年我国人均国内生产总值作为WTP阈值时，与多西他赛相比，替雷利珠单抗单药治疗既往接受过含铂双药方案化疗后疾病进展或不可耐受的局部晚期或转移性鳞状或非鳞状NSCLC患者具有经济性。

Abstract

OBJECTIVE

From the perspective of China’s healthcare system， to evaluate the cost-effectiveness of tislelizumab in patients with locally advanced or metastatic squamous or non-squamous non-small cell lung cancer （NSCLC） whose disease progresses or is intolerable after receiving platinum-containing dual chemotherapy in the past.

METHODS

Rationale-303 research data were used to construct a partitioned survival model. The model period was set to be 21 days and simulated to 120 months. Using quality-adjusted life year （QALY） as a health output index， the incremental cost-effectiveness ratio （ICER） was calculated by discounting cost and health output with a discount rate of 5%. Single-factor sensitivity analysis and probability sensitivity analysis were performed to verify the robustness of the basic analysis results.

RESULTS

Cost-utility analysis results showed that the ICER of tislelizumab group was 65 653.52 yuan/QALY， compared with docetaxel group. This means that the regimen of tislelizumab was more cost-effective than the docetaxel regimen when the willingness-to-pay threshold （WTP） was 3 times China’s gross domestic product （GDP） per capita in 2023 （268 200 yuan/QALY）. The results of single-factor sensitivity analysis showed that the three parameters that had a greater impact on ICER were the prices of tislelizumab， docetaxel and pemetrexed. The results of the probabilistic sensitivity analysis showed that the probabilities of the above two treatment regimens being cost-effective were both 50% when the WTP threshold was approximately 65 000 yuan/QALY. The probability of tislelizumab regimen being cost-effective was 100% when the WTP threshold was ≥134 000 yuan/QALY.

CONCLUSIONS

From the perspective of China’s healthcare system， when taking 3 times China’s GDP per capita in 2023 as the WTP threshold， tislelizumab is cost-effective for patients with locally advanced or metastatic squamous or non-squamous NSCLC after receiving platinum-containing dual chemotherapy in the past， compared with docetaxel.

关键词

Keywords

references

HAN B F ， ZHENG R S ， ZENG H M ， et al . Cancer incidence and mortality in China，2022 [J ] . J Natl Cancer Cent ， 2024 ， 4 （ 1 ）： 47 - 53 .

ROSELL R ， KARACHALIOU N . Large-scale screening for somatic mutations in lung cancer [J ] . Lancet ， 2016 ， 387 （ 10026 ）： 1354 - 1356 .

SOCINSKI M A ， BONDARENKO I ， KARASEVA N A ， et al . Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer：final results of a phase Ⅲ trial [J ] . J Clin Oncol ， 2012 ， 30 （ 17 ）： 2055 - 2062 .

HAYASHI H ， OKAMOTO I ， MORITA S ， et al . Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer [J ] . Ann Oncol ， 2012 ， 23 （ 6 ）： 1537 - 1541 .

周彩存，王洁，王宝成，等 . 中国非小细胞肺癌免疫检查点抑制剂治疗专家共识：2020年版 [J ] . 中国肺癌杂志， 2021 ， 24 （ 4 ）： 217 - 235 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南2023 [M ] . 北京：人民卫生出版社， 2023 ： 126 .

LU S ， WANG J ， YU Y ， et al . Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC （Rationale-304）：a randomized phase 3 trial [J ] . J Thorac Oncol ， 2021 ， 16 （ 9 ）： 1512 - 1522 .

LUO X ， ZHOU Z ， ZENG X H ， et al . The cost-effectiveness of tislelizumab plus chemotherapy for locally advanced or metastatic nonsquamous non-small cell lung cancer [J ] . Front Pharmacol ， 2022 ， 13 ： 935581 .

ZHOU C C ， HUANG D Z ， FAN Y ， et al . Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC （Rationale-303）：a phase 3，open-label，rando- mized controlled trial [J ] . J Thorac Oncol ， 2023 ， 18 （ 1 ）： 93 - 105 .

何艺敏，念紫琳，刘文彬，等 . PD-1/PD-L1抑制剂联合疗法一线治疗晚期非小细胞肺癌的成本-效用分析 [J ] . 中国现代应用药学， 2024 ， 41 （ 13 ）： 1820 - 1829 .

赵荧荧，居文祥，张小涵，等 . 替雷利珠单抗联合化疗一线治疗晚期或转移性食管鳞状细胞癌的成本-效果分析 [J ] . 中国医院药学杂志， 2025 ， 45 （ 4 ）： 418 - 426 .

中国抗癌协会肿瘤临床化疗专业委员会，中国抗癌协会肿瘤支持治疗专业委员会，冯继锋，等 . 肿瘤化疗导致的中性粒细胞减少诊治中国专家共识： 2023版 [J ] . 中华肿瘤杂志， 2023 ， 45 （ 7 ）： 575 - 583 .

中国中西医结合学会血液病专业委员会 . 肿瘤放化疗后白细胞减少症中西医结合治疗专家共识：2022年版 [J ] . 中华肿瘤防治杂志， 2022 ， 29 （ 23 ）： 1641 - 1646，1652 .

NAFEES B ， LLOYD A J ， DEWILDE S ， et al . Health state utilities in non-small cell lung cancer：an international study [J ] . Asia Pac J Clin Oncol ， 2017 ， 13 （ 5 ）： e195 - e203 .

刘国恩 . 中国药物经济学评价指南2020 [M ] . 北京：中国市场出版社， 2020 ： 27 - 46 .

WANG H ， LONG Y C ， XU Y ， et al . Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer [J ] . Front Public Health ， 2023 ， 11 ： 1137255 .

HUO G W ， LIU W J ， KANG S ， et al . Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer：a cost-effectiveness analysis [J ] . Front Pharmacol ， 2023 ， 14 ： 1131219 .

刘一，刘青，黄琳，等 . 程序性死亡受体1抑制剂：替雷利珠单抗 [J ] . 临床药物治疗杂志， 2022 ， 20 （ 1 ）： 37 - 42 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-utility analysis of capivasertib combined with fulvestrant in the second-line treatment of HR+/HER2－ advanced breast cancer

Cost-utility analysis of capecitabine metronomic chemotherapy combined with aromatase inhibitor as first-line treatment for HR+/HER2－ metastatic breast cancer

Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in the second-line treatment for HER2-positive metastatic breast cancer

Economic evaluation of NALIRIFOX regimen for first-line treatment of metastatic pancreatic cancer

Pharmacoeconomic evaluation of durvalumab combined with chemotherapy as first-line therapy for advanced biliary tract cancer

Related Author

ZHANG Yang

KANG Shuo

WANG Xiaohui

HOU Yibing

FU Xiangxia

LIU Huanlong

LIU Guoqiang

ZHANG Yuxi

Related Institution

Dept. of Nursing， the Second Hospital of Hebei Medical University

School of Pharmacy， Hebei Medical University

Medical Insurance Office， the Second Hospital of Hebei Medical University

Dept. of Pharmacy，the Second Hospital of Hebei Medical University

Dept. of Clinical Pharmacy， Hebei Medical University Third Hospital

⁰